Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma

PURPOSE: This phase III trial evaluated the efficacy and safety of pazopanib versus placebo in patients with locally advanced renal cell carcinoma (RCC) at high risk for relapse after nephrectomy. PATIENTS AND METHODS: A total of 1,538 patients with resected pT2 (high grade) or ≥ pT3, including N1,...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Oncol
Päätekijät: Motzer, Robert J., Haas, Naomi B., Donskov, Frede, Gross-Goupil, Marine, Varlamov, Sergei, Kopyltsov, Evgeny, Lee, Jae Lyun, Melichar, Bohuslav, Rini, Brian I., Choueiri, Toni K., Zemanova, Milada, Wood, Lori A., Reaume, M. Neil, Stenzl, Arnulf, Chowdhury, Simon, Lim, Ho Yeong, McDermott, Ray, Michael, Agnieszka, Bao, Weichao, Carrasco-Alfonso, Marlene J., Aimone, Paola, Voi, Maurizio, Doehn, Christian, Russo, Paul, Sternberg, Cora N.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2017
Aiheet:
ORIGINAL REPORTS
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6018511/
https://ncbi.nlm.nih.gov/pubmed/28902533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.73.5324
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia